JP2013090933A - タウリナミド誘導体ならびに生物学的に許容可能な塩および酸を含み、低濃度のヘパリンが添加された抗菌性ロッキング溶液 - Google Patents
タウリナミド誘導体ならびに生物学的に許容可能な塩および酸を含み、低濃度のヘパリンが添加された抗菌性ロッキング溶液 Download PDFInfo
- Publication number
- JP2013090933A JP2013090933A JP2012279870A JP2012279870A JP2013090933A JP 2013090933 A JP2013090933 A JP 2013090933A JP 2012279870 A JP2012279870 A JP 2012279870A JP 2012279870 A JP2012279870 A JP 2012279870A JP 2013090933 A JP2013090933 A JP 2013090933A
- Authority
- JP
- Japan
- Prior art keywords
- heparin
- range
- catheter
- units per
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/88—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms six-membered rings with three ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/043—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Agronomy & Crop Science (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials For Medical Uses (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
【解決手段】以下の溶液を含む、ロッキング溶液組成物:(A)少なくとも1つのタウリナミド誘導体;(B)生物学的に許容可能な酸および生物学的に許容可能なその塩から成る群から選択される少なくとも1つの化合物;および(C)低濃度のヘパリン。
【選択図】なし
Description
男性に対して:
VB = 0.3669 x (H)3 + 0.03219xW + 0.604
女性に対して:
VB = 0.3561 x (H)3 + 0.03308xW + 0.1833、
ここにおいて、Hは、患者の身長(メーター)であり、Wは患者の全体重(キログラム)である。得られる血液体積はリッターで表される(1000をかけて、mlの体積を得る)。典型的な患者の試験値を用いると、男性に対しては5000から6000 ml、女性に対しては4000から5000 mlの血液体積の範囲が得られる。中点値(mid-range value)である5000 mlを、以下の計算に使用したが、性別ごとおよび患者ごとの広い多様性を、常に考慮しなければならない。
(L濃度)(流出したカテーテル体積) = (血液濃度) x (血液体積)
(ここにおいて、ほとんどの日常的な場合において、流出したカテーテル体積 = 1 mlおよび血液体積 = 5000 mlである。)
上記にて設定した安全な上限(すなわち、0.5ユニット/ml)および典型的な血液体積5000 mlを用いて、カテーテルロック溶液中1 ml当りヘパリン2500ユニットという基準上限(nominal upper limit)が得られる。
Claims (24)
- 血液カテーテルにおける感染および流動性の低下を治療しおよび予防するための、以下の溶液を含む、ロッキング溶液組成物:
a. 少なくとも1つのタウリナミド誘導体;
b. 組み合わせによる、生物学的に許容可能な酸および該酸の生物学的に許容可能な塩であって、前記組み合わせのpHが、タウリナミド誘導体の抗菌活性を増強させる範囲に収まるようにするもの;および
c. 低濃度のヘパリン、ここにおいて、該ヘパリンの濃度は、タウリナミド誘導体と停滞した血液との反応を防ぐのに十分であり、しかし、前記溶液が患者の血流中に排除および/または流出された場合に患者が出血する危険性は低いものとなるよう、十分に低い。 - 請求項1に記載の組成物であって、前記生物学的に許容可能な酸が、クエン酸および乳酸の群から選択され、ならびに、前記生物学的に許容可能な塩が、クエン酸塩および乳酸塩の群から選択される組成物。
- 請求項1に記載の組成物であって、前記タウリナミド誘導体がタウロリジンであり、前記生物学的に許容可能な酸がクエン酸であり、前記生物学的に許容可能な塩がクエン酸塩であり、およびpHの範囲が5.2から6.5である組成物。
- 請求項3に記載の組成物であって、低濃度のヘパリンが、1 ml当り、50から2500ユニットの範囲である組成物。
- 請求項4に記載の組成物であって、低濃度のヘパリンが、1 ml当り、50から1750ユニットの範囲である組成物。
- 請求項4に記載の組成物であって、低濃度のヘパリンが、1 ml当り、50から500ユニットの範囲である組成物。
- 請求項4に記載の組成物であって、低濃度のヘパリンが、1 ml当り、50から150ユニットの範囲である組成物。
- クエン酸塩およびクエン酸との組み合わせでタウロリジンを含むカテーテルロッキング溶液により生じる抗菌活性および流動性の低下に対する抵抗性を、pHを5.2から6.5の範囲に維持することで増強し、ならびに、低濃度のヘパリンを添加することで、カテーテルでのタウロリジンと血液との反応からカテーテルを保護する方法。
- 請求項8に記載の方法であって、低濃度のヘパリンが、1 ml当り、50から2500ユニットの範囲である方法。
- 請求項8に記載の方法であって、低濃度のヘパリンが、1 ml当り、50から1750ユニットの範囲である方法。
- 請求項8に記載の方法であって、低濃度のヘパリンが、1 ml当り、50から500ユニットの範囲である方法。
- 請求項8に記載の方法であって、低濃度のヘパリンが、1 ml当り、50から150ユニットの範囲である方法。
- 血液透析カテーテルにおける感染および開存性の減少を治療しおよび予防するための、以下を含むロッキング溶液を含む組成物:
a. 少なくとも1つのタウリナミド誘導体;および
b. 低濃度のヘパリン、ここにおいて、該ヘパリンの濃度は、タウリナミド誘導体と停滞した血液との反応を防ぐのに十分であり、しかし、前記溶液が患者の血流中に排除および/または流出された場合に患者が出血する危険性は低いものとなるよう、十分に低い。 - 請求項13に記載の組成物であって、前記タウリナミド誘導体がタウロリジンである組成物。
- 請求項13に記載の組成物であって、ヘパリンが、1 ml当り、50から2500ユニットの範囲の濃度で添加される組成物。
- 請求項13に記載の組成物であって、低濃度のヘパリンが、1 ml当り、50から1750ユニットの範囲である方法。
- 請求項13に記載の組成物であって、低濃度のヘパリンが、1 ml当り、50から500ユニットの範囲である方法。
- 請求項13に記載の組成物であって、低濃度のヘパリンが、1 ml当り、50から150ユニットの範囲である方法。
- カテーテルにおける感染および流動性の低下を治療しおよび予防するための、以下の溶液を含む、ロッキング溶液組成物:
a. 少なくとも1つのタウリナミド誘導体;
b. 前記組成物のpHを、タウリナミド誘導体の抗菌活性を増強する範囲に収めるのに十分な濃度の、生物学的に許容可能な酸;および
c. 低濃度のヘパリン、ここにおいて、該ヘパリンの濃度は、タウリナミド誘導体の反応を防ぐのに十分であり、しかし、前記溶液が患者の血流中に排除および/または流出された場合に患者が出血する危険性は低いものとなるよう、十分に低い。 - 請求項19に記載の組成物であって、前記タウリナミド誘導体がタウロリジンである組成物。
- 請求項19に記載の組成物であって、ヘパリンが、1 ml当り、50から2500ユニットの範囲の濃度で添加される組成物。
- 請求項19に記載の組成物であって、低濃度のヘパリンが、1 ml当り、50から1750ユニットの範囲である組成物。
- 請求項19に記載の組成物であって、低濃度のヘパリンが、1 ml当り、50から500ユニットの範囲である組成物。
- 請求項19に記載の組成物であって、低濃度のヘパリンが、1 ml当り、50から150ユニットの範囲である組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/979,547 | 2004-11-02 | ||
US10/979,547 US7696182B2 (en) | 2004-11-02 | 2004-11-02 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007540313A Division JP2008518739A (ja) | 2004-11-02 | 2005-10-12 | タウリナミド誘導体ならびに生物学的に許容可能な塩および酸を含み、低濃度のヘパリンが添加された抗菌性ロッキング溶液 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013090933A true JP2013090933A (ja) | 2013-05-16 |
JP5805617B2 JP5805617B2 (ja) | 2015-11-04 |
Family
ID=36262855
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007540313A Withdrawn JP2008518739A (ja) | 2004-11-02 | 2005-10-12 | タウリナミド誘導体ならびに生物学的に許容可能な塩および酸を含み、低濃度のヘパリンが添加された抗菌性ロッキング溶液 |
JP2012279870A Active JP5805617B2 (ja) | 2004-11-02 | 2012-12-21 | タウリナミド誘導体ならびに生物学的に許容可能な塩および酸を含み、低濃度のヘパリンが添加された抗菌性ロッキング溶液 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007540313A Withdrawn JP2008518739A (ja) | 2004-11-02 | 2005-10-12 | タウリナミド誘導体ならびに生物学的に許容可能な塩および酸を含み、低濃度のヘパリンが添加された抗菌性ロッキング溶液 |
Country Status (9)
Country | Link |
---|---|
US (9) | US7696182B2 (ja) |
EP (2) | EP1814562B1 (ja) |
JP (2) | JP2008518739A (ja) |
CN (2) | CN101094679A (ja) |
DE (1) | DE202005022124U1 (ja) |
DK (1) | DK1814562T3 (ja) |
ES (2) | ES2456946T3 (ja) |
PT (1) | PT1814562E (ja) |
WO (1) | WO2006049813A2 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA007594B1 (ru) | 2001-11-26 | 2006-12-29 | Джинентех, Инк. | Конструкция катетера и области ее применения |
US7696182B2 (en) * | 2004-11-02 | 2010-04-13 | Nd Partners, Llc | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
CA2668347C (en) * | 2006-11-07 | 2017-06-20 | Genentech, Inc. | Tissue plasminogen activator variant uses |
JP5417691B2 (ja) * | 2007-07-19 | 2014-02-19 | 株式会社ジェイ・エム・エス | 弱酸を含有する血管内留置カテーテルのロック溶液 |
KR20110096539A (ko) * | 2008-12-05 | 2011-08-30 | 가부시끼가이샤 제이엠에스 | 아세트산을 함유하는 혈관 내에 유치된 카테터의 로크 용액 및 그 로크 용액을 수납한 용기 |
WO2010088192A1 (en) * | 2009-01-27 | 2010-08-05 | Telelflex Medical Incorporated | Bacteriostatic catheter lock containing glycerol |
US9248093B2 (en) | 2009-06-11 | 2016-02-02 | Becton, Dickinson And Company | Catheter locking solution having antimicrobial and anticoagulation properties |
WO2011019710A2 (en) * | 2009-08-10 | 2011-02-17 | Proviflo, Llc | Catheter lock solutions utilizing tocopheraol and mid-chain fatty acids |
US8951577B2 (en) * | 2010-08-03 | 2015-02-10 | Teleflex Medical Incorporated | Antimicrobial hydrochloric acid catheter lock solution and method of use |
WO2014004498A1 (en) * | 2012-06-25 | 2014-01-03 | Medical Components, Inc. | Citrate anticoagulant underloaded syringe for catheter locking |
WO2016201269A2 (en) | 2015-06-11 | 2016-12-15 | Proviflo, Llc | Graft-port hemodialysis systems, devices and methods |
SI3167873T1 (sl) | 2015-11-11 | 2019-06-28 | Christian Edwin Weis | Vodna raztopina kondenzacijskih proizvodov tavrinamida in metilenglikola za uporabo kot antiinfekcijsko sredstvo pri vsaditvi naprav v srčni kirurgiji |
JP7003053B2 (ja) * | 2016-03-28 | 2022-01-20 | コーメディクス・インコーポレーテッド | 野外殺菌装置及び血管コネクタキット |
CA3047165A1 (en) | 2016-12-27 | 2018-07-05 | Vasonics, Llc | Catheter housing |
CA3076366C (en) | 2017-09-22 | 2023-05-16 | Becton, Dickinson And Company | 4% trisodium citrate solution for use as a catheter lock solution |
CN117295550A (zh) | 2021-04-30 | 2023-12-26 | 惠而浦公司 | 过滤器组件 |
US11738120B1 (en) * | 2022-04-14 | 2023-08-29 | Cormedix Inc. | Synthesis of taurolidine, purity profiles and polymorphs |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63500943A (ja) * | 1985-09-20 | 1988-04-07 | ラインミュラ−,ヨハネス | 血液凝固阻止剤 |
US6350251B1 (en) * | 2000-01-18 | 2002-02-26 | Biolink Corporation | Biocidal locks |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1124285A (en) | 1964-10-06 | 1968-08-21 | Geistlich Soehne Ag | Novel perhydro-1,2,4-thiadiazine dioxides-(1,1), their preparation and compositionscontaining them |
GB1557163A (en) | 1975-06-24 | 1979-12-05 | Geistlich Soehne Ag | Dental care preparations |
US4107305A (en) | 1975-08-04 | 1978-08-15 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Treatment of endotoxaemia |
US4337251A (en) | 1979-05-09 | 1982-06-29 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Method of avoiding and removing adhesions |
CA1190855A (en) | 1980-09-03 | 1985-07-23 | Rolf W. Pfirrmann | Treatment of osteitis |
GB8328073D0 (en) | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compounds |
GB8328074D0 (en) | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compositions |
GB8328111D0 (en) | 1983-10-20 | 1983-11-23 | Geistlich Soehne Ag | Chemical compounds |
GB8408447D0 (en) | 1984-04-02 | 1984-05-10 | Roussel Lab Ltd | 1,2,4-thiadiazines |
DE3506288A1 (de) | 1984-09-06 | 1986-03-13 | Johannes 7900 Ulm Reinmüller | Vorrichtung zum einlegen in wunden und wundhoehlen |
DE3513938A1 (de) | 1985-04-18 | 1986-10-23 | Merck Patent Gmbh, 6100 Darmstadt | Cytostatikahaltiges pharmakadepot |
GB8514052D0 (en) | 1985-06-04 | 1985-07-10 | Geistlich Soehne Ag | Compositions |
GB8514055D0 (en) | 1985-06-04 | 1985-07-10 | Geistlich Soehne Ag | Chemical substance |
US4587284A (en) | 1985-06-14 | 1986-05-06 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Absorbent polymer material and its preparation |
DE3542972A1 (de) | 1985-12-05 | 1987-06-11 | Merck Patent Gmbh | Pharmakadepot |
US5210083A (en) | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
DE3812524A1 (de) | 1988-04-15 | 1989-10-26 | Fresenius Ag | Dialysier- und spuelloesung fuer die intraperitoneale verabreichung mit antimikrobieller ausruestung |
GB8813033D0 (en) | 1988-06-02 | 1988-07-06 | Geistlich Soehne Ag | Chemical compound |
US5573771A (en) | 1988-08-19 | 1996-11-12 | Osteomedical Limited | Medicinal bone mineral products |
US5032615A (en) | 1989-10-31 | 1991-07-16 | The Regents Of The University Of California | Continuous hemodialysis using citrate |
GB9005856D0 (en) | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
US5176665A (en) | 1991-01-18 | 1993-01-05 | Alza Corporation | Antimicrobial device for urine drainage container |
DE4137544C2 (de) | 1991-11-12 | 1998-07-30 | Kramer Axel | Antimikrobielle Wirkstoffkombination auf der Basis von Sauerstoff abspaltenden Verbindungen |
SE9201413L (sv) | 1992-04-30 | 1993-10-31 | Stiftelsen Foer Medicinsk Tekn | Beredning och sätt för aferesframställning av trombocytkoncentrat med väsentligt förlängd hållbarhet |
GB9216155D0 (en) | 1992-07-30 | 1992-09-09 | Geistlich Soehne Ag | Treatment of dentoalveolar infections |
US5688516A (en) | 1992-11-12 | 1997-11-18 | Board Of Regents, The University Of Texas System | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices |
US5362754A (en) | 1992-11-12 | 1994-11-08 | Univ. Of Tx Md Anderson Cancer Center | M-EDTA pharmaceutical preparations and uses thereof |
EP0698398A1 (en) | 1994-08-23 | 1996-02-28 | Becton, Dickinson and Company | Blood collection device |
US5603921A (en) | 1995-03-13 | 1997-02-18 | Whalen Biomedical Incorporated | Medicated dental floss and method of preparation |
US5954691A (en) | 1995-06-07 | 1999-09-21 | Biolink Corporation | Hemodialysis access apparatus |
GB9600426D0 (en) | 1996-01-10 | 1996-03-13 | Ed Geistlich Sohne A G | Compositions |
US5766220A (en) | 1996-02-29 | 1998-06-16 | Moenning; Stephen P. | Apparatus and method for protecting a port site opening in the wall of a body cavity |
GB9626795D0 (en) | 1996-12-23 | 1997-02-12 | Geistlich Soehne Ag | Combating infection in delivery systems |
DE19708782C1 (de) | 1997-03-04 | 1998-08-06 | Claus Prof Dr Herdeis | Verfahren zur Herstellung von 2-Aminoethansulfonylazid-säureadditionssalzen, 2-Aminoethansulfonylazid-hydrochlorid sowie dessen Verwendung |
US6447488B2 (en) | 1998-03-19 | 2002-09-10 | Biolink Corporation | Apparatus for the dialysis of blood, method for fabricating the same, and method for the dialysis of blood |
US6166007A (en) | 1998-07-02 | 2000-12-26 | Sodemann; Klaus | Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof |
AU5689199A (en) * | 1998-08-25 | 2000-03-14 | Ash Medical Systems, Inc. | Method of enhancing catheter patency using a citrate salt catheter lock solution |
US6174537B1 (en) | 1998-09-25 | 2001-01-16 | Becton, Dickinson And Company | Catheter flush solution and method for its use |
US6821968B2 (en) | 2001-09-26 | 2004-11-23 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Stable taurolidine electrolyte solutions |
US6685694B2 (en) * | 1999-07-23 | 2004-02-03 | Vasca, Inc. | Methods and kits for locking and disinfecting implanted catheters |
AU2001232873A1 (en) | 2000-01-20 | 2001-07-31 | Biolink Corporation | Anti-microbial barrier |
EP1245247A1 (en) * | 2001-03-28 | 2002-10-02 | Biolink Corporation | Biocidal locks |
US6803363B2 (en) * | 2002-05-31 | 2004-10-12 | Nd Partners, Llc | Peritoneal dialysis solution with taurolidine |
DE60311958T2 (de) | 2003-02-03 | 2007-11-08 | Polaschegg, Hans-Dietrich, Dr. | Zusammensetzung zur Prävention von Infektionen durch subkutane Prothesen |
EP1814561A4 (en) | 2004-10-29 | 2012-12-19 | Biocryst Pharm Inc | THEROPUTICAL FUROPYRIMIDINES AND THIENOPYRIMIDINES |
US7696182B2 (en) * | 2004-11-02 | 2010-04-13 | Nd Partners, Llc | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
-
2004
- 2004-11-02 US US10/979,547 patent/US7696182B2/en active Active
-
2005
- 2005-10-12 CN CNA2005800457016A patent/CN101094679A/zh active Pending
- 2005-10-12 DE DE202005022124.4U patent/DE202005022124U1/de not_active Ceased
- 2005-10-12 PT PT58033911T patent/PT1814562E/pt unknown
- 2005-10-12 EP EP05803391.1A patent/EP1814562B1/en not_active Revoked
- 2005-10-12 EP EP14150248.4A patent/EP2742945B1/en active Active
- 2005-10-12 DK DK05803391.1T patent/DK1814562T3/da active
- 2005-10-12 WO PCT/US2005/036451 patent/WO2006049813A2/en active Application Filing
- 2005-10-12 JP JP2007540313A patent/JP2008518739A/ja not_active Withdrawn
- 2005-10-12 CN CN201210513004.0A patent/CN103083353B/zh active Active
- 2005-10-12 ES ES05803391.1T patent/ES2456946T3/es active Active
- 2005-10-12 ES ES14150248T patent/ES2951567T3/es active Active
-
2010
- 2010-03-12 US US12/661,183 patent/US20100331277A1/en not_active Abandoned
-
2011
- 2011-09-02 US US13/199,605 patent/US8541393B2/en active Active
-
2012
- 2012-12-21 JP JP2012279870A patent/JP5805617B2/ja active Active
-
2013
- 2013-09-24 US US14/034,877 patent/US9339036B2/en active Active
-
2016
- 2016-05-17 US US15/156,772 patent/US20170128629A1/en not_active Abandoned
-
2018
- 2018-03-05 US US15/911,527 patent/US20190038813A1/en not_active Abandoned
-
2019
- 2019-11-21 US US16/691,073 patent/US20200330651A1/en not_active Abandoned
-
2021
- 2021-02-16 US US17/176,718 patent/US20210236698A1/en not_active Abandoned
-
2023
- 2023-03-08 US US18/118,842 patent/US20240108791A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63500943A (ja) * | 1985-09-20 | 1988-04-07 | ラインミュラ−,ヨハネス | 血液凝固阻止剤 |
US6350251B1 (en) * | 2000-01-18 | 2002-02-26 | Biolink Corporation | Biocidal locks |
Also Published As
Publication number | Publication date |
---|---|
ES2951567T3 (es) | 2023-10-23 |
US9339036B2 (en) | 2016-05-17 |
JP5805617B2 (ja) | 2015-11-04 |
DK1814562T3 (da) | 2014-04-14 |
WO2006049813A3 (en) | 2006-11-23 |
US20210236698A1 (en) | 2021-08-05 |
WO2006049813A2 (en) | 2006-05-11 |
US20100331277A1 (en) | 2010-12-30 |
ES2456946T3 (es) | 2014-04-24 |
CN103083353B (zh) | 2016-06-08 |
DE202005022124U1 (de) | 2014-05-06 |
EP1814562A4 (en) | 2010-10-27 |
EP2742945B1 (en) | 2023-06-28 |
JP2008518739A (ja) | 2008-06-05 |
US20140243323A1 (en) | 2014-08-28 |
US20240108791A1 (en) | 2024-04-04 |
CN103083353A (zh) | 2013-05-08 |
PT1814562E (pt) | 2014-04-17 |
US20170128629A1 (en) | 2017-05-11 |
US20200330651A1 (en) | 2020-10-22 |
EP1814562B1 (en) | 2014-01-08 |
EP1814562A2 (en) | 2007-08-08 |
EP2742945A1 (en) | 2014-06-18 |
US20120208802A1 (en) | 2012-08-16 |
CN101094679A (zh) | 2007-12-26 |
US20060094690A1 (en) | 2006-05-04 |
US7696182B2 (en) | 2010-04-13 |
US20190038813A1 (en) | 2019-02-07 |
US8541393B2 (en) | 2013-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5805617B2 (ja) | タウリナミド誘導体ならびに生物学的に許容可能な塩および酸を含み、低濃度のヘパリンが添加された抗菌性ロッキング溶液 | |
KR101549238B1 (ko) | 카테테르 잠금을 위한 항미생물성 조성물 및 방법 | |
JP5718913B2 (ja) | 抗菌性および抗凝固性を有するカテーテルロック溶液 | |
US6958049B1 (en) | Method of enhancing catheter patency using a citrate salt catheter lock solution | |
US20050215978A1 (en) | Method of enhancing catheter patency using a citrate salt catheter lock solution | |
US9433209B2 (en) | Transdermal venous access locking solutions | |
EP1107807B1 (en) | Use of citrate in a catheter lock solution | |
JP2005517460A (ja) | 光酸化剤を含むカテーテルロック溶液 | |
US20100249747A1 (en) | Transdermal venous access locking solution | |
CA2846891C (en) | Transdermal venous access locking solutions | |
US9427498B2 (en) | Syringe treated with transdermal venous access locking solutions and method of treating the syringe | |
Canaud et al. | Dialock: pilot trial of a new vascular port access device for hemodialysis | |
US20230015541A1 (en) | 16% Sodium Citrate Solution for Use as an Antimicrobial Catheter Lock Solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140318 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140616 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140918 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150617 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150804 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150902 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5805617 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |